Legend Biotech Stock in Brief

By Kim Brooks • Thursday, June 22 09:45 • Permanent Link

Mid-cap Health Care company Legend Biotech has moved -1.2% so far today on a volume of 18,833, compared to its average of 918,977. In contrast, the S&P 500 index moved -0.0%.

Legend Biotech trades -11.37% away from its average analyst target price of $82.5 per share. The 10 analysts following the stock have set target prices ranging from $65.0 to $90.0, and on average have given Legend Biotech a rating of buy.

Anyone interested in buying LEGN should be aware of the facts below:

Legend Biotech has moved 44.8% over the last year, and the S&P 500 logged a change of 15.0%
Based on its trailing earnings per share of -3.34, Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -21.9 while the S&P 500 average is 15.97
LEGN has a forward P/E ratio of -27.1 based on its forward 12 month price to earnings (EPS) of $-2.7 per share
Its Price to Book (P/B) ratio is 18.5 compared to its sector average of 4.16
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Based in Somerset, the company has 1,390 full time employees and a market cap of $13.19 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.